IDEntification of New Predisposition Genes in Differentiated THYroid Cancer (NCT05014698) | Clinical Trial Compass
TerminatedNot Applicable
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
Stopped: end-of-study visit not completed within the protocol timeframe
France34 participantsStarted 2022-02-23
Plain-language summary
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
Who can participate
Age range8 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Probant subjects
* Minor or adult subject
* Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
* Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
* Patient affiliated to a valid social security plan
Relative subjects
* Adult subjects
* Subject agreeing to sign the study consent and the biocollection consent
* Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
* Patient affiliated to a social security plan
Exclusion Criteria:
* Subject refusing to participate
* Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
* Subjects under guardianship, curatorship or safeguard of justice or not socially insured
* Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)
What they're measuring
1
Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer